Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (COGT): 9 pipeline candidates · 1 upcoming catalyst · ~29 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
29.0 months
D/E 0.49 · 0% dilution
Lead: Phase 3
9 candidates
1 upcoming, next in ~1293d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Cogent Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.7B
Cash
$241.6M
Quarterly Burn
$86.9M
Runway
29.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| Bezuclastinib | Phase 2 |
| bezuclastinib (CGT9486) | Phase 3 |
| CGT4255 | Phase 1/Phase 2 |
| CGT4824 | Phase 3 |
| CGT4859 | Phase 3 |
| CGT6297 | Phase 1 |
| cgt9486 | Phase 3 |
| JAK2 program | Preclinical |
| KRAS program | Preclinical |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
305
Total value held
$7.13B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 23,122,748 | $890.0M |
| blackrock, inc. | 16,045,014 | $617.6M |
| vanguard capital management llc | 13,789,918 | $530.8M |
| janus henderson group plc | 11,930,250 | $459.3M |
| deerfield management company, l.p. | 9,043,903 | $348.1M |
| vanguard portfolio management llc | 7,333,333 | $282.3M |
| state street corp | 5,663,543 | $218.0M |
| rtw investments, lp | 5,458,675 | $210.1M |
| goldman sachs group inc | 4,434,054 | $170.7M |
| kynam capital management, lp | 4,037,331 | $155.4M |
Showing top 10 of 305 institutional holders of Cogent Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cogent Biosciences, Inc.'s pipeline?
Cogent Biosciences, Inc. (COGT) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cogent Biosciences, Inc.'s lead drug candidate?
Cogent Biosciences, Inc.'s most advanced tracked candidate is Bezuclastinib (Phase 2) for SSM; Systemic Mastocytoses, Indolent; Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors.
What is Cogent Biosciences, Inc.'s next catalyst?
Cogent Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S" — expected January 1, 2030.
What is Cogent Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cogent Biosciences, Inc. has approximately 29.0 months of cash runway.
What is Cogent Biosciences, Inc.'s market capitalization?
Cogent Biosciences, Inc.'s market capitalization is approximately $5.7B.
Get the full picture on Cogent Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.